Castle Biosciences Study Finds DecisionDx-UM Plus PRAME Outperforms Gene Mutation Analysis in Uveal Melanoma Prognosis
I'm PortAI, I can summarize articles.
Castle Biosciences Inc. announced that their combination of DecisionDx-UM and PRAME gene expression outperformed next-generation sequencing-based gene mutation analysis in predicting outcomes for uveal melanoma patients. The study, published in Nature Communications, showed improved metastasis-free and overall survival predictions. The enhanced performance is attributed to DecisionDx-UM's ability to measure gene activity from both tumor and surrounding immune cells, offering a comprehensive tumor microenvironment assessment.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments